Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Will Ver­tex’s “pipeline-in-a-prod­uct” pay off?

That’s the bet be­hind the com­pa­ny’s $4.9 bil­lion ac­qui­si­tion of Alpine Im­mune Sci­ences and its mid-stage IgA nephropa­thy drug, which is de­signed to in­hib­it two key cy­tokines.

The com­pa­nies an­nounced the deal last week, tout­ing povetaci­cept’s po­ten­tial in IgA nephropa­thy (IgAN) and hint­ing at its broad­er am­bi­tions to treat au­toim­mune con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER